Dr. Reddy’s Laboratories announces the launch of Melphalan Hydrochloride for Injection in the U.S. market.
Dr. Reddy’s Laboratories Ltd. has launched Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran* (melphalan hydrochloride) for Injection in the United States market as approved by the U.S. Food and Drug Administration.
The Alkeran brand and generic had U.S. sales of approximately $107 million MAT (moving annual total) for the most recent twelve months ending in October 2017, according to IMS Health**.
Dr. Reddy’s Melphalan Hydrochloride for Injection is available in a carton containing one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.
* Alkeran® is a registered trademark of Apotex, Inc.
** IMS National Sales Perspective: Retail and Non-Retail MAT October 2017